Sei Investments Co. Has $31.61 Million Stake in Repligen Co. (NASDAQ:RGEN)

Sei Investments Co. lifted its position in Repligen Co. (NASDAQ:RGEN) by 12.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 219,604 shares of the biotechnology company’s stock after buying an additional 24,662 shares during the quarter. Sei Investments Co. owned about 0.39% of Repligen worth $31,610,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Resources Management Corp CT ADV bought a new stake in Repligen in the third quarter worth $37,000. Quarry LP increased its position in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the last quarter. UMB Bank n.a. raised its holdings in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 110 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock worth $53,000 after buying an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on RGEN shares. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Royal Bank of Canada lifted their price target on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Finally, Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $178.64.

Insider Buying and Selling

In other news, Director Margaret Pax acquired 250 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Stock Performance

NASDAQ RGEN opened at $141.95 on Wednesday. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $187.25. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.97 billion, a P/E ratio of -278.33, a PEG ratio of 4.54 and a beta of 0.95. The company’s 50-day simple moving average is $155.62 and its 200 day simple moving average is $148.36.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.